Canadian impact of CLSI aminoglycoside breakpoint changes for selected gram-negative bacteria

Ellen Germaine Avery; Taylor Laughlin; Kevin Brown; Larissa M Matukas; Elizabeth Leung

doi:10.1017/ash.2025.10035

Canadian impact of CLSI aminoglycoside breakpoint changes for selected gram-negative bacteria

Antimicrob Steward Healthc Epidemiol. 2025 Jun 30;5(1):e138. doi: 10.1017/ash.2025.10035. eCollection 2025.

Authors

Ellen Germaine Avery¹, Taylor Laughlin², Kevin Brown³, Larissa M Matukas^#^{1

2}, Elizabeth Leung^#^{4

5

6}

Affiliations

¹ Department of Laboratory Medicine & Pathobiology, University of Toronto, Toronto, ON, Canada.
² Department of Laboratory Medicine, Unity Health Toronto, Toronto, ON, Canada.
³ Public Health Ontario, Toronto, ON, Canada.
⁴ St. Michael's Hospital, Department of Pharmacy, Unity Health Toronto, Toronto, ON, Canada.
⁵ Li Ka Shing Knowledge Institute, Toronto, ON, Canada.
⁶ Leslie Dan Faculty of Pharmacy, University of Toronto, Toronto, ON, Canada.

^# Contributed equally.

Abstract

We evaluated the impact of recent revisions to the Clinical and Laboratory Standards Institute (CLSI) aminoglycoside breakpoints on susceptibility within Enterobacterales and Pseudomonas aeruginosa at a Canadian academic hospital. While the aminoglycoside breakpoint changes minimally affected overall susceptibility, the impact of these changes was notable within beta-lactamase producing Enterobacterales.